Company news
Whitehawk Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
March 5, 2024
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 4, 2024
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
February 29, 2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
January 25, 2024
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
January 18, 2024
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
November 7, 2023
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
November 5, 2023
Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update
October 31, 2023
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
October 18, 2023
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 11, 2023
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium
October 4, 2023
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
October 2, 2023
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
October 1, 2023
Aadi Bioscience to Participate at Upcoming Investor Conferences
September 4, 2023
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update
August 8, 2023
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update
August 1, 2023
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2023
Aadi Bioscience to Participate in Upcoming Investor Events
May 22, 2023
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
May 9, 2023
Aadi Bioscience to Report First Quarter 2023 Results and Operational Update
May 2, 2023
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 13, 2023
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023
April 5, 2023
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
March 27, 2023
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
March 26, 2023
Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
March 14, 2023
Aadi Bioscience Announces Leadership Transition
March 2, 2023
Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference
February 21, 2023
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
November 16, 2022
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
November 8, 2022
Aadi Bioscience Announces Planned Leadership Transition
November 7, 2022
Aadi Bioscience to Present at Upcoming Investor Conferences
November 2, 2022
Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update
November 1, 2022
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
October 11, 2022
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
September 21, 2022
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
August 31, 2022
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
August 9, 2022
Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
July 27, 2022
Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
June 22, 2022
Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
May 31, 2022
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
May 30, 2022
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
May 25, 2022
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 11, 2022
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
May 8, 2022
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
May 3, 2022
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
April 27, 2022
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
April 17, 2022
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
April 7, 2022
Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes
March 30, 2022
Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 16, 2022
Calls
The 5 newest of 10 calls. Every call is listed under its year.
- Whitehawk Therapeutics (NASDAQ:WHWK) Q4 2024 Earnings Call
Mar 19, 2025
Transcript - Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call
Aug 7, 2024
Transcript - Aadi Bioscience, Inc. (AADI) Q1 2024 Earnings Call
May 8, 2024
Transcript - Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call
Mar 13, 2024
Transcript - Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call
Nov 8, 2023
Transcript
Decks
- Investor Presentation (August 2026)
Investor deck · 36 slides · August 2026